Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Application based on results from the TROPION-Breast01 Phase III trial
This acquisition enables MTD to open new, strategic markets
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
Cipla completes transfer of Generics Business Undertaking
Subscribe To Our Newsletter & Stay Updated
